Paradoxical antidiabetogenic effect of γ-interferon in DP-BB rats

Diabetes

Volumn 47, Issue 1, 1998, Pages 32-38

  Nicoletti, Ferdinando ^a,f   Zaccone, Paola ^b   Di Marco, Roberto ^b   Magro, Gaetano ^b   Grasso, Sebastiano ^b   Stivala, Franca ^b   Calori, Giliola ^c   Mughini, Lanfranco ^b   Meroni, Pier Luigi ^d   Garotta, Gianni ^e  

^a UNIVERSITY OF MILAN   (Italy)

^b UNIVERSITY OF CATANIA   (Italy)

^c SAN RAFFAELE HOSPITAL   (Italy)

^d Policlinico Foundation   (Italy)

^e GLAXOSMITHKLINE   (United States)

^f NONE   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIDIABETIC AGENT; GAMMA INTERFERON ANTIBODY; INTERLEUKIN 2 RECEPTOR; POLYINOSINIC POLYCYTIDYLIC ACID; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; AUTOIMMUNITY; CONTROLLED STUDY; DIABETOGENESIS; DOSE RESPONSE; FEMALE; HISTOPATHOLOGY; IMMUNOMODULATION; INSULITIS; INTRAPERITONEAL DRUG ADMINISTRATION; MALE; NONHUMAN; PERITONEUM MACROPHAGE; PRIORITY JOURNAL; RAT; TREATMENT OUTCOME;

EID: 0031975108     PISSN: 00121797     EISSN: None     Source Type: Journal    
DOI: 10.2337/diab.47.1.32     Document Type: Article

References (63)

1. Bach JF: Insulin-dependent diabetes mellitus as an autoimmune disease. Endocr Rev 15:516-542, 1994
2. Rossini AA, Handler ES, Mordes JP, Greiner DL Animal models of human disease. Human autoimmune diabetes mellitus: lessons from BB rats and NOD mice - caveat emptor. Clin Immunol Immunopathol 74:2-9, 1995
3. Kolb H, Kolb-Bachofen V, Roep BO: Autoimmune versus inflammatory type 1 diabetes: a controversy? Immunol Today 16:170-172, 1995
4. Bendtzen K: Immune hormones' (cytokines) pathogenic role in autoimmune rheumatic diseases and endocrine diseases. Autoimmunity 2:177-189, 1989
5. Mandrup-Poulsen T, Helqvist S, Wogensen LD, Molvig J, Pociot F, Johannesen J, Nerup J: Cytokine and free radicals as effector molecules in the destruction of pancreatic beta cells. Curr Top Microbiol Immunol 164:169-193, 1990
6. Rabinovitch A: Roles of cytokines in IDDM pathogenesis and islet beta cell destruction. Diabetes Rev 1:215-240, 1992
7. Murase N, Lieberman I, Nalesnik A, Mintz DH, Todo S, Drash AL, Starzl TE: Effect of FK 506 on spontaneous diabetes in BB rats. Diabetes 39:1584-1586, 1990
8. Nicoletti F, Meroni PL, Barcellini W, Grasso S, Borghi MO, Lunetta M, Di Marco R, Stefani S, Mughini L: FK 506 prevents diabetes in diabetes-prone BB/Wor rats. Int J Immunopharmacol 13:1027-1030, 1991
9. Nicoletti F, Di Marco R, Morrone S, Zaccone P, Lembo D, Grasso S, Santoni A, Meroni PL, Bendtzen K: Reduction of spontaneous diabetes in diabetesprone BB rats with the novel immunosuppressant fusidic acid effect on T cell proliferation and production of interferon-gamma. Immunology 81:317-321, 1994
10. Rabinovitch A: Immunoregulatory and cytokine imbalances in the pathogenesis of IDDM: therapeutic intervention by immunostimulation? Diabetes 43:613-621, 1994
11. Nicoletti F, Zaccone P, Di Marco R, Lunetta M, Magro G, Grasso S, Meroni PL, Garotta G: Prevention of spontaneous autoimmune diabetes in diabetes-prone BB rats by prophylactic treatment with anti-rat interferon-γ antibody. Endocrinology 138:281-288, 1997
12. Rabinovitch A, Suarez-Pinzon W, El-Sheikh A, Sorensen O, Power RF: Cytokine gene expression in pancreatic islet-infiltrating leukocytes of BB rats: expression of Th1 cytokines correlate with β-cell destructive insulitis and IDDM. Diabetes 45:749-754, 1996
13. Zipris D, Greiner DL, Malkani S, Whalen B, Mordes JP, Rossini AA: Cytokine gene expression in islets and thyroids of BB rats: IFN-gamma and IL-12p40 mRNA increase with age in both diabetic and insulin-treated nondiabetic rats. J Immunol 156:1315-1321, 1996
14. Nicoletti F, Meroni PL, Landolfo S, Gariglio M, Guzzardi S, Barcellini W, Lunetta M, Mughini L, Zanussi C: Prevention of diabetes in BB/Wor rats with monoclonal antibodies against rat γ-interferon. Lancet 336:319, 1990
15. Campbell IL, Kay TWH, Oxbrow L, Harrison LC: Essential role for interferon-γ and interleukin-6 in autoimmune insulin-dependent diabetes in NOD/Whei mice. J Clin Invest 87:739-742, 1991
16. Debray-Sachs M, Carnaud C, Boitard C, Cohen H, Gresser I, Bedossa P, Bach JF: Prevention of diabetes in NOD mice treated with antibody to murine IFN-γ. J Autoimmun 4:237-248, 1991
17. Pennline KJ, Roque-Gaffney E, Monahan M: Recombinant human IL-10 prevents the onset of diabetes in nonobese diabetic mouse. Clin Immunol Immunopathol 71:169-175, 1994
18. Nicoletti F, Zaccone P, Di Marco R, Di Mauro M, Magro G, Grasso S, Mughini L, Meroni PL, Garotta G: The effects of a nonimmunogenic form of murine soluble interferon-gamma receptor on the development of autoimmune diabetes in NOD mouse. Endocrinology 137:5567-5575, 1996
19. Cockfield SM, Ramassar V, Urmson J, Halloran PF: Multiple low dose streptozotocin induces systemic MHC expression in mice by triggering T cells to release IFN-γ. J Immunol 142:1120-1128, 1989
20. Kurschner C, Ozmen L, Garotta G, Dembic Z: IFN-γ receptor-Ig fusion proteins: half-life, inimunogenicity and in vivo activity. J Immunol 149:4096-4100, 1992
21. Campbell IL, Oxbrow L, Koulmanda M, Harrison LC: IFN-γ induces islet cell MHC antigens and enhances autoimmune, streptozotocin-induced diabetes in the mouse. J Immnnol 140:1111-1116, 1988
22. von Herrath MG, Oldstone MBA: Interferon-γ is essential for destruction of β cells and development of insulin-dependent diabetes mellitus. J Exp Med 185:531-539, 1997
23. Sarvetnick N, Liggit D, Pitts SL, Hansen SE, Stewart TA: Insulin-dependent diabetes mellitus induced in transgenic mice by ectopic expression of MHC class II antigens and interferon-γ. Cell 52:773-782, 1988
24. Sarvetnick N, Shizuru J, Liggit D, Martin L, McIntyre B, Gregory A, Parslow W, Stewart T: Loss of pancreatic islet tolerance induced by beta cell expression of interferon-γ. Nature 346:844-847, 1990
25. Kallmann BA, Huther M, Tubes M, Feldkamp J, Bertrams J, Gries FA, Lampeter EF, Kolb HK: Systemic bias of cytokine production toward cell-mediated immune regulation in IDDM and toward humoral immunity in Graves' disease. Diabetes 46:237-243, 1997
26. Nicoletti F, Scalia G, Condorelli F, Stivala A, Leonardi C, Steinsvag PO, La Rosa L, Lunetta M: Anti-cytomegalovirus IgM and IgG antibodies, islet cell antibodies and gamma interferon serum levels in newly diagnosed IDDM patients. Int J Immunopathol Pharmacol 4:99-106, 1991
27. Hussain MJ, Peakman M, Gallati H, Lo SSS, Hawa M, Viberti GC, Watkins PJ, Leslie RDG, Vergani D: Elevated serum levels of macrophage derived cytokines precede and accompany the onset of IDDM. Diabetologia 39:60-69, 1996
28. Foulis AK, McGill M, Farquharson MA: Insulitis in type 1 (insulin-dependent) diabetes mellitus in man: macrophages, lymphocytes and interferon-gamma containing cells. J Pathol 165:97-103, 1991
29. Ozmen L, Fountoulakis M, Garotta G: A novel solid-phase test to study the binding of IFN-γ to its receptor. J Immunol Methods 147:261-270, 1992
30. Duner KI: A new kinetic single-stage Limulus amoebocyte lysate method for the detection of endotoxin in water and plasma. J Biochem Biophys Methods 26:31-139, 1933
31. Nicoletti F, Borghi MO, Meroni PL, Barcellini W, Fain C, Di Marco R, Menta R, Schorlemmer HU, Bruno G, Magro G, Grasso S: Prevention of cyclophosphamide-induced diabetes in NOD/Whei mouse with deoxyspergualin. Clin Exp Immunol 91:232-236, 1993
32. Lapchak PH, Guilbert LJ, Rabinovitch A: Tumor necrosis factor production is deficient in diabetes-prone BB rats and can be corrected by complete Freund's adjuvant: a possible immunoregulatory role of tumor necrosis factor in the prevention of diabetes. Clin Immunol Immunopathol 65:129-134, 1992
33. Nicoletti F, Meroni PL, Di Marco R, Grasso S, Barcellini W, Borghi MO, Lunetta M, Mughini L, Menta R, Sohorlemmer HU, Zanussi C: The effects of deoxyspergualin on the development of diabetes in diabetes-prone BB rats. Scand J Immunol 36:415-420, 1992
34. Hosszufalusi N, Chan E, Granger G, Charles MA: Quantitative analyses comparing all major spleen cell phenotypes in BB and normal rats: autoimmune imbalance and double negative T cells associated with resistant, prone and diabetic animals. J Autoimmun 5:305-318, 1992
35. Like AA, Guberski LD, Butler L: Influence of environmental agents on frequency and tempo of diabetes in BBA/Wor rats. Diabetes 40:259-262, 1991
36. Satoh, J, Seino H, Shintani S, Tanaki SI, Ohteki T, Masada T, Nobunaga T, Oteki T, Kumagai K, Toyota T: Inhibition of type 1 diabetes in BB rats with recombinant human tumor necrosis factor-α. J Immunol 145:1395-1399, 1990
37. Jacob CO, Aiso S, Michie SA, McDevitt HO, Acha-Orbea H: Prevention of diabetes in nonobese diabetic mice by tumor necrosis factor (TNF): similarities between TNF-α and interleukin-1. Proc Natl Acad Sci USA 87:968-972, 1990
38. Satoh J, Seino H, Tanaka SI, Shintani S, Ohta S, Tamura K, Sawai T, Nobunaga T, Oteki T, Kumagai K, Toyota T: Recombinant human tumor necrosis factor-α suppresses autoimmune diabetes in nonobese diabetic mice. J Clin Invest 84:1345-1348, 1989
39. Wilson CA, Jacobs C, Baker P, Baskin DG, Dower S, Lernmark A, Toivola B, Vertrees S, Wilson D: IL-1β modulation of spontaneous autoimmune diabetes and thyroiditis in the BB rat. J Immunol 144:3784-3788, 1990
40. Dayer-Metroz MD, Duhamel D, Rufner N, Izui S, Carmichaels D, Wollheim CB, Thompson RC, Dayer JM: IL-1 receptor antagonist delays spontaneous autoimmune diabetes in BB rats (Abstract). Eur J Clin Invest 22:A50, 1992
41. Nicoletti F, Di Marco R, Barcellini W, Magro G, Schorlemmer HU, Kurrle R, Lunetta M, Grasso S, Zaccone P, Meroni PL: Protection from experimental autoimmune diabetes in the nonobese diabetic mouse with soluble interleukin-1 receptor. Eur J Immunol 24:1843-1847, 1994
42. Zielasek J, Burkart V, Naylor P, Goldstein A, Kiesel U, Kolb H: Interleukin-2 dependent control of disease development in spontaneously diabetic BB rats. Immunology 69:209-214, 1990
43. Hahn HJ, Lucke S, Kloting I, Volk HD, Von Baher R, Diamanstein T: Curing BB rats of freshly manifested diabetes by short treatment with a combination of a monoclonal anti-interleukin-2 receptor antibody and a subtherapeutic dose of cyclosporin A. Eur J Immunol 17:1075-1081, 1987
44. Kelley VE, Gaulton GN, Hattori M, Ikegami H, Eisenbarth G, Strom TB: Anti-interleukin 2 receptor antibody suppresses murine diabetic insulitis and lupus nephritis. J Immunol 150:59-61, 1980
45. Trimbleau S, Germann T, Gately MK, Adorini L: The role of IL-12 in the induction of organ-specific autoimmune diseases. Immunol Today 16:383-386, 1995
46. Yang XD, Tisch R, Singer SM, Cao ZA, Liblau RS, Schreiber RD, McDevitt HO: Effect of tumor necrosis factor-α on insulin-dependent diabetes mellitus in NOD mice. I. The early development of autoimmunity and the diabetogenic process. J Exp Med 180:995-1004, 1994
47. Shik-Lee M, Mueller R, Wicker LS, Peterson LB, Sarvetnick N: IL-10 is necessary and sufficient for autoimmune diabetes in conjunction with NOD MHC homozygosity. J Exp Med 183:2663-2668, 1996
48. Jacob CO, Aiso S, Schreiber RD, McDevitt HO: Monoclonal anti-tumor necrosis factor antibody renders non-obese diabetic mice hypersensitive to irradiation and enhances insulitis development. Int Immunol 4:611-614, 1992
49. Heremans HR, Dijkmans R, Sobis H, Vandekerchove F, Biliau A: Regulation by interferons of the local inflammatory response to lipopolysaccharide. J Immunol 138:4175-4180, 1987
50. Kolb H, Worz-Pagenstert U, Kleemann R, Rothe H, Roswell P, Scott FW: Cytokine gene expression in the BB rat pancreas: natural course and impact of bacterial vaccines. Diabetologia 39:1448-1454, 1996
51. Rabinovitch A, Suarez-Pinzon WL, Lapchak PH, Meager A, Power RF: Tumor necrosis factor mediates the protective effect of Freund's adjuvant against autoimmune diabetes in BB rats. J Autoimmun 8:357-366, 1995
52. Landolfo S, Garotta G: IFN-λ: an immunomodulatory and proinflammatory lymphokine. J Immunol Res 9:81-94, 1991
53. Sadelain MWJ, Qin H-V, Sumoski W, Parfrey N, Singh B, Rabinovitch A: Prevention of diabetes in the BB rat by early immunotherapy using Freund's adjuvant. J Autoimmun 3:671-680, 1990
54. Bendtzen K: Cytokines and natural regulators of cytokines. Immunol Lett 43:111-123, 1994
55. Wahl SM, Allen JB, Ohura K, Chenoweth DE, Hand AR: Interferon-gamma inhibits inflammatory cell recruitment and the evolution of bacterial cell-wall-induced arthritis. J Immunol 146:95-100, 1991
56. 8+ T cells Is mediated by interferon-gamma and is defective in chronic progressive multiple sclerosis. J Clin Invest 95:2711-2719, 1995
57. Novelli F, Di Pierro F, di Celle PF, Bertini S, Affaticati P, Garotta G, Forni G: Environmental signals influencing expression of the IFN-γ receptor on human T cells control whether IFN-γ promotes proliferation or apoptosis. J Immunol 152:496-504, 1994
58. + T lymphocytes alone is insufficient to induce diabetes in diabetes-resistant BB/Wor rats. Am J Pathol 136:565-574, 1990
59. Thomson AW, Starzl TE: FK 506 and autoimmune disease: perspective and prospects. Autoimmunity 12:303-313, 1992
60. Waguri M, Hanafusa T, Itoh N, Imagawa A, Miyagawa J, Kawata S, Kono N, Kuwaijima M, Matsuzawa Y: Occurrence of IDDM during Interferon therapy for chronic viral hepatitis. Diabetes Res Clin Pract 23:33-36, 1994
61. Guerci AP, Guerci B, Levy-Marchal C, Ongagna J, Ziegler O, Candiloros H, Guerci O, Drouin P: Onset of insulin-dependent diabetes mellitus after interferon-alpha therapy for hairy cell leukaemia. Lancet i: 1167-1168, 1994
62. Panitch HS, Heracl RL, Schindler J, Johnson KP: Treatment of multiple sclerosis with gamma-interferon: exacerbations associated with activation of the immune system. Neurology 37:1097-1120, 1987
63. Cannon G, Pincus SH, Emkey RD, Denes A, Cohen SA, Wolfe F, Saway PA, Jaffer AM, Weaver AL, Cogen L, Schindler JD: Double-blind trial of recombinant gamma-interferon versus placebo in the treatment of rheumatoid arthritis. Arthritis Rheum 31:1297-1305, 1989